NYSE:MYOV - Myovant Sciences Stock Price, Price Target & More

$20.73 -1.79 (-7.95 %)
(As of 04/20/2018 08:37 AM ET)
Previous Close$22.52
Today's Range$20.14 - $22.69
52-Week Range$9.92 - $24.14
Volume675,300 shs
Average Volume82,591 shs
Market Capitalization$1.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta-2.44

About Myovant Sciences (NYSE:MYOV)

Myovant Sciences logoMyovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MYOV
CUSIPN/A
Phone203-318-9709

Debt

Debt-to-Equity Ratio0.35%
Current Ratio5.04%
Quick Ratio5.04%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book7.48

Profitability

EPS (Most Recent Fiscal Year)($1.70)
Net Income$-83,440,000.00
Net MarginsN/A
Return on Equity-90.86%
Return on Assets-74.94%

Miscellaneous

Employees36
Outstanding Shares60,990,000

How to Become a New Pot Stock Millionaire

Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How were Myovant Sciences' earnings last quarter?

Myovant Sciences (NYSE:MYOV) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.28. View Myovant Sciences' Earnings History.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, June, 13th 2018. View Earnings Estimates for Myovant Sciences.

What price target have analysts set for MYOV?

5 brokers have issued 12 month price targets for Myovant Sciences' shares. Their predictions range from $18.00 to $25.00. On average, they anticipate Myovant Sciences' stock price to reach $21.00 in the next year. View Analyst Ratings for Myovant Sciences.

What are Wall Street analysts saying about Myovant Sciences stock?

Here are some recent quotes from research analysts about Myovant Sciences stock:
  • 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (4/18/2018)
  • 2. Cowen Inc analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017)

Who are some of Myovant Sciences' key competitors?

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:
  • Dr. Lynn Seely, Chief Exec. Officer, Pres and Exec. Director (Age 59)
  • Mr. Frank L. Karbe, Principal Financial & Accounting Officer (Age 50)
  • Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 50)
  • Ms. Julie Tran MBA, MSHR, Exec. Director of HR
  • Mr. Bryan Selby, Sr. VP of Product Devel.

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Has Myovant Sciences been receiving favorable news coverage?

Headlines about MYOV stock have trended somewhat positive on Friday, Accern reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Myovant Sciences earned a media sentiment score of 0.09 on Accern's scale. They also gave headlines about the company an impact score of 45.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $20.73.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $1.37 billion. The company earns $-83,440,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Myovant Sciences employs 36 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 203-318-9709 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (MYOV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Myovant Sciences (NYSE:MYOV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Myovant Sciences in the last 12 months. Their average twelve-month price target is $21.00, suggesting that the stock has a possible upside of 1.30%. The high price target for MYOV is $25.00 and the low price target for MYOV is $18.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.803.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.00$22.50$22.50$20.00
Price Target Upside: 1.30% upside67.54% upside67.54% upside34.41% upside

Myovant Sciences (NYSE:MYOV) Consensus Price Target History

Price Target History for Myovant Sciences (NYSE:MYOV)

Myovant Sciences (NYSE:MYOV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2018BarclaysDowngradeOverweight -> Equal Weight$18.00HighView Rating Details
11/14/2017CowenReiterated RatingBuyN/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingBuy$20.00N/AView Rating Details
10/4/2017JMP SecuritiesReiterated RatingOutperform$23.00 -> $25.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> OutperformHighView Rating Details
11/21/2016CitigroupInitiated CoverageBuy$17.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Myovant Sciences (NYSE:MYOV) Earnings History and Estimates Chart

Earnings by Quarter for Myovant Sciences (NYSE:MYOV)

Myovant Sciences (NYSE:MYOV) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.35 EPS
Next Year EPS Consensus Estimate: $-1.58 EPS

Myovant Sciences (NYSE MYOV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/13/2018        
2/13/2018Q3 2018($0.42)($0.70)ViewN/AView Earnings Details
11/13/2017Q2 2018($0.38)($0.50)ViewN/AView Earnings Details
8/10/2017Q1 2018($0.29)($0.39)ViewN/AView Earnings Details
6/14/2017Q4 2017($0.37)ViewN/AView Earnings Details
2/13/2017Q3 2017($0.33)($0.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Myovant Sciences (NYSE:MYOV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Myovant Sciences (NYSE MYOV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 81.44%
Insider Trading History for Myovant Sciences (NYSE:MYOV)
Institutional Ownership by Quarter for Myovant Sciences (NYSE:MYOV)

Myovant Sciences (NYSE MYOV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Holdings Ltd. DexxonMajor ShareholderBuy1,110,015$20.27$22,500,004.05View SEC Filing  
3/19/2018Pharmaceuticals Interna TakedaMajor ShareholderBuy7,420,625$18.67$138,543,068.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Myovant Sciences (NYSE MYOV) News Headlines

Source:
DateHeadline
Form 4 Myovant Sciences Ltd. For: Apr 16 Filed by: KARBE FRANKForm 4 Myovant Sciences Ltd. For: Apr 16 Filed by: KARBE FRANK
www.streetinsider.com - April 19 at 9:31 AM
Myovant Sciences (MYOV) Raised to "Hold" at Zacks Investment ResearchMyovant Sciences (MYOV) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:46 AM
Zacks Investment Research Upgrades Myovant Sciences (MYOV) to HoldZacks Investment Research Upgrades Myovant Sciences (MYOV) to Hold
www.americanbankingnews.com - April 9 at 5:52 PM
BioSci Research On Myovant Sciences (Part I): Is This A Big Winner In The Making?BioSci Research On Myovant Sciences (Part I): Is This A Big Winner In The Making?
seekingalpha.com - April 9 at 9:45 AM
Myovant Sciences (MYOV) Given Buy Rating at Robert W. BairdMyovant Sciences (MYOV) Given Buy Rating at Robert W. Baird
www.americanbankingnews.com - April 7 at 9:54 PM
Zacks: Brokerages Expect Myovant Sciences (MYOV) Will Announce Earnings of -$0.77 Per ShareZacks: Brokerages Expect Myovant Sciences (MYOV) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 7 at 5:20 PM
Myovant Sciences (MYOV) Lifted to Hold at Zacks Investment ResearchMyovant Sciences (MYOV) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:39 AM
Myovant Sciences (MYOV) Upgraded to Hold by ValuEngineMyovant Sciences (MYOV) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM
Myovant Sciences (MYOV) Downgraded by Barclays to "Equal Weight"Myovant Sciences (MYOV) Downgraded by Barclays to "Equal Weight"
www.americanbankingnews.com - April 5 at 11:32 AM
Form 4 Myovant Sciences Ltd. For: Apr 02 Filed by: VIKING GLOBAL PERFORMANCE LLCForm 4 Myovant Sciences Ltd. For: Apr 02 Filed by: VIKING GLOBAL PERFORMANCE LLC
www.streetinsider.com - April 5 at 8:57 AM
Myovant Sciences Ltd (MYOV) Given Average Rating of "Buy" by BrokeragesMyovant Sciences Ltd (MYOV) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 1:34 AM
Myovant Sciences Ltd (MYOV) Major Shareholder Buys $22,500,004.05 in StockMyovant Sciences Ltd (MYOV) Major Shareholder Buys $22,500,004.05 in Stock
www.americanbankingnews.com - April 4 at 10:22 PM
Myovant announces Private Placement and At-the-Market Offering ProgramMyovant announces Private Placement and At-the-Market Offering Program
seekingalpha.com - April 3 at 4:27 PM
BRIEF-Myovant Sciences Says May Offer, Sell Cos Common Shares Having Aggregate Offering Price Of Up To $100 MlnBRIEF-Myovant Sciences Says May Offer, Sell Co's Common Shares Having Aggregate Offering Price Of Up To $100 Mln
www.reuters.com - April 3 at 4:27 PM
BRIEF-Myovant Sciences Says ‍On April 2, Co Entered A Share Purchase Agreement With Roivant SciencesBRIEF-Myovant Sciences Says ‍On April 2, Co Entered A Share Purchase Agreement With Roivant Sciences
www.reuters.com - April 3 at 9:49 AM
Myovant Sciences (MYOV) Upgraded to Hold by Zacks Investment ResearchMyovant Sciences (MYOV) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 27 at 7:26 PM
Form 4 Myovant Sciences Ltd. For: Mar 19 Filed by: TAKEDA PHARMACEUTICAL CO LTDForm 4 Myovant Sciences Ltd. For: Mar 19 Filed by: TAKEDA PHARMACEUTICAL CO LTD
www.streetinsider.com - March 22 at 9:46 AM
Myovant Sciences Ltd (MYOV) Major Shareholder Acquires $138,543,068.75 in StockMyovant Sciences Ltd (MYOV) Major Shareholder Acquires $138,543,068.75 in Stock
www.americanbankingnews.com - March 21 at 10:10 PM
 Analysts Anticipate Myovant Sciences Ltd (MYOV) to Announce -$0.77 EPS Analysts Anticipate Myovant Sciences Ltd (MYOV) to Announce -$0.77 EPS
www.americanbankingnews.com - March 21 at 7:18 PM
Contrasting Myovant Sciences (MYOV) and Chiasma (CHMA)Contrasting Myovant Sciences (MYOV) and Chiasma (CHMA)
www.americanbankingnews.com - March 10 at 3:22 PM
Myovant Sciences to Present at Upcoming Investor ConferencesMyovant Sciences to Present at Upcoming Investor Conferences
finance.yahoo.com - March 7 at 9:39 AM
Myovant Sciences Ltd (MYOV) Shares Sold by Emory UniversityMyovant Sciences Ltd (MYOV) Shares Sold by Emory University
www.americanbankingnews.com - March 4 at 3:02 PM
Head to Head Analysis: Myovant Sciences (MYOV) & Sonoma Pharmaceuticals (SNOA)Head to Head Analysis: Myovant Sciences (MYOV) & Sonoma Pharmaceuticals (SNOA)
www.americanbankingnews.com - February 21 at 1:30 AM
Zacks Investment Research Downgrades Myovant Sciences (MYOV) to SellZacks Investment Research Downgrades Myovant Sciences (MYOV) to Sell
www.americanbankingnews.com - February 20 at 6:58 AM
 Analysts Expect Myovant Sciences Ltd (MYOV) to Post -$0.46 EPS Analysts Expect Myovant Sciences Ltd (MYOV) to Post -$0.46 EPS
www.americanbankingnews.com - February 15 at 9:10 PM
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
finance.yahoo.com - February 13 at 4:28 PM
Contrasting Peregrine Pharmaceuticals (CDMO) & Myovant Sciences (MYOV)Contrasting Peregrine Pharmaceuticals (CDMO) & Myovant Sciences (MYOV)
www.americanbankingnews.com - February 5 at 1:39 PM
Myovant Sciences Ltd (MYOV) Expected to Announce Earnings of -$0.42 Per ShareMyovant Sciences Ltd (MYOV) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - January 29 at 11:16 PM
Financial Survey: Anika Therapeutics (ANIK) and Myovant Sciences (MYOV)Financial Survey: Anika Therapeutics (ANIK) and Myovant Sciences (MYOV)
www.americanbankingnews.com - January 14 at 11:30 AM
Myovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare ConferenceMyovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:10 AM
Myovant Sciences (MYOV) & Argos Therapeutics (ARGS) Financial ComparisonMyovant Sciences (MYOV) & Argos Therapeutics (ARGS) Financial Comparison
www.americanbankingnews.com - January 3 at 10:14 AM
Analyzing Myovant Sciences (MYOV) & Alexion Pharmaceuticals (ALXN)Analyzing Myovant Sciences (MYOV) & Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - December 29 at 3:24 PM
Myovant Sciences (MYOV) & Ocera Therapeutics (OCRX) Financial AnalysisMyovant Sciences (MYOV) & Ocera Therapeutics (OCRX) Financial Analysis
www.americanbankingnews.com - December 28 at 9:29 AM
-$0.42 Earnings Per Share Expected for Myovant Sciences Ltd (MYOV) This Quarter-$0.42 Earnings Per Share Expected for Myovant Sciences Ltd (MYOV) This Quarter
www.americanbankingnews.com - December 27 at 10:50 AM
Head to Head Comparison: Myovant Sciences (MYOV) and Argos Therapeutics (ARGS)Head to Head Comparison: Myovant Sciences (MYOV) and Argos Therapeutics (ARGS)
www.americanbankingnews.com - December 19 at 3:16 AM
Financial Review: Onconova Therapeutics (ONTX) versus Myovant Sciences (MYOV)Financial Review: Onconova Therapeutics (ONTX) versus Myovant Sciences (MYOV)
www.americanbankingnews.com - December 17 at 11:32 AM
Myovant Sciences (MYOV) and Syndax Pharmaceuticals (SNDX) Financial ContrastMyovant Sciences (MYOV) and Syndax Pharmaceuticals (SNDX) Financial Contrast
www.americanbankingnews.com - December 14 at 5:40 PM
Myovant Sciences (MYOV) versus Its Peers Financial AnalysisMyovant Sciences (MYOV) versus Its Peers Financial Analysis
www.americanbankingnews.com - December 11 at 3:34 PM
Head-To-Head Contrast: Auxilium Pharmaceuticals (AUXL) vs. Myovant Sciences (MYOV)Head-To-Head Contrast: Auxilium Pharmaceuticals (AUXL) vs. Myovant Sciences (MYOV)
www.americanbankingnews.com - December 11 at 1:26 AM
Critical Comparison: Myovant Sciences (MYOV) vs. Its RivalsCritical Comparison: Myovant Sciences (MYOV) vs. Its Rivals
www.americanbankingnews.com - December 10 at 5:22 PM
Comparing Myovant Sciences (MYOV) & The CompetitionComparing Myovant Sciences (MYOV) & The Competition
www.americanbankingnews.com - December 10 at 5:20 PM
 Brokerages Expect Myovant Sciences Ltd (MYOV) to Announce -$0.42 Earnings Per Share Brokerages Expect Myovant Sciences Ltd (MYOV) to Announce -$0.42 Earnings Per Share
www.americanbankingnews.com - December 9 at 11:42 PM
Contrasting Cardiome Pharma (CRME) & Myovant Sciences (MYOV)Contrasting Cardiome Pharma (CRME) & Myovant Sciences (MYOV)
www.americanbankingnews.com - December 9 at 5:30 AM
Myovant Sciences (MYOV) and The Competition Head to Head AnalysisMyovant Sciences (MYOV) and The Competition Head to Head Analysis
www.americanbankingnews.com - December 8 at 1:30 AM
Comparing Myovant Sciences (MYOV) & Its RivalsComparing Myovant Sciences (MYOV) & Its Rivals
www.americanbankingnews.com - December 8 at 1:30 AM
Critical Contrast: Myovant Sciences (MYOV) and Its CompetitorsCritical Contrast: Myovant Sciences (MYOV) and Its Competitors
www.americanbankingnews.com - December 3 at 9:48 PM
Myovant Sciences (MYOV) versus The Competition Head to Head ComparisonMyovant Sciences (MYOV) versus The Competition Head to Head Comparison
www.americanbankingnews.com - November 30 at 3:12 AM
Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive ConferenceMyovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference
finance.yahoo.com - November 22 at 6:02 AM
 Brokerages Anticipate Myovant Sciences Ltd. (MYOV) Will Post Earnings of -$0.42 Per Share Brokerages Anticipate Myovant Sciences Ltd. (MYOV) Will Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - November 21 at 11:26 PM
Head to Head Survey: Myovant Sciences (MYOV) & Its CompetitorsHead to Head Survey: Myovant Sciences (MYOV) & Its Competitors
www.americanbankingnews.com - November 21 at 11:20 AM

SEC Filings

Myovant Sciences (NYSE:MYOV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Myovant Sciences (NYSE:MYOV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Myovant Sciences (NYSE MYOV) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.